Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase IIIb Trial to Evaluate the Effect of Survodutide on Cardiac Structure and Function of Participants With Overweight or Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); (ELEVATE-LIVER)

NCT07850063 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07850063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07850063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase IIIb Trial to Evaluate the Effect of Survodutide on Cardiac Structure and Function of Participants With Overweight or Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); (ELEVATE-LIVER)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 23, 2026
Completion date
April 29, 2029
Enrollment
600 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatotic liver disease, obesity